EchoGo® Heart Failure vs Zio XT ECG Monitoring System
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (EchoGo® Heart Failure) is designed for the AI-powered detection of Heart Failure with preserved Ejection Fraction (HFpEF) by analyzing echocardiograms. In contrast, Tool B (Zio XT ECG Monitoring System) provides continuous, long-term ECG monitoring via a wearable biosensor to detect and diagnose cardiac arrhythmias. While both leverage AI in cardiology and serve similar specialties, they address distinct diagnostic needs using different data sources and methodologies.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Heart Failure is an AI platform designed to analyze routine echocardiograms specifically for the detection of Heart Failure with preserved Ejection Fraction (HFpEF). In contrast, the Zio XT ECG Monitoring System utilizes a wearable biosensor for up to 14 days of continuous cardiac monitoring, focusing on the detection and diagnosis of arrhythmias.
EchoGou00ae Heart Failure analyzes existing routine echocardiogram video clips using its AI platform to provide insights. The Zio XT ECG Monitoring System involves a patient wearing a single-lead ECG biosensor for continuous data collection, which is then analyzed by an FDA-cleared AI algorithm and expert review via a cloud-based platform.
EchoGou00ae Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis. For the Zio XT ECG Monitoring System in the US, Medicare rates were proposed at approximately $229-$260.35 under CPT codes 93247 (greater than 7 days up to 15 days) and 93243 (greater than 48 hours up to 7 days).
EchoGou00ae Heart Failure delivers insights within 20 minutes of analyzing routine echo video clips. The Zio XT ECG Monitoring System provides analysis and reporting after the continuous monitoring period, which can last up to 14 days.
For EchoGou00ae Heart Failure, the patient experience involves undergoing a routine echocardiogram, with the AI platform analyzing the collected video clips. With the Zio XT ECG Monitoring System, patients wear a water-resistant, single-lead ECG biosensor for up to 14 days, which has no external leads and includes a patient-activated button for symptomatic event logging, boasting high patient compliance.
EchoGou00ae Heart Failure offers seamless integration with existing workflows and IT stacks, utilizing a DICOM workflow for report delivery directly to PACS. The Zio XT ECG Monitoring System operates on a cloud-based software platform (ZEUS) for data storage, analysis, and reporting, requiring no on-premise hardware.
More Comparisons
Backers
Who funded each tool's parent company.